A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer
Authors:
- 1 January 2015
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (1) , 27-36
Abstract
No abstract availableKeywords
Funding Information
- Pfizer Pharma
This publication has 33 references indexed in Scilit:
- Targeting Mitochondrial STAT3 with the Novel Phospho-Valproic Acid (MDC-1112) Inhibits Pancreatic Cancer Growth in MicePLOS ONE, 2013
- Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancerInvestigational New Drugs, 2011
- A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinomaInvestigational New Drugs, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Current State of Surgical Management of Pancreatic CancerCancers, 2011
- PKC 412 small‐molecule tyrosine kinase inhibitorCancer, 2007
- Molecular genetics of pancreatic intraepithelial neoplasiaJournal of Hepato-Biliary-Pancreatic Surgery, 2007
- Tyrosine kinase inhibitors and gemcitabine: New treatment options in pancreatic cancer?Drug Resistance Updates, 2006
- Pancreatic cancer growth is inhibited by blockade of VEGF-RIISurgery, 2003
- SOP 02: Evaluation and Selection of a Clinical Trial Proposal for CESAROncology Research and Treatment, 2003